ArriVent BioPharma Enters Material Definitive Agreement

TL;DR

ArriVent BioPharma just signed a big deal, filing an 8-K with new agreements and financials.

AI Summary

On January 21, 2025, ArriVent BioPharma, Inc. entered into a material definitive agreement. The company also disclosed information under Regulation FD and filed financial statements and exhibits as part of this 8-K filing.

Why It Matters

This filing indicates a significant new agreement for ArriVent BioPharma, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.

Key Players & Entities

• ArriVent BioPharma, Inc. (company) — Registrant
• January 21, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share AVBP The Nasdaq
• $47.0 million — d near-term milestone payments totaling $47.0 million in cash and is eligible to receive up t
• $1.16 billion — n cash and is eligible to receive up to $1.16 billion in development, regulatory and sales mi

Filing Documents

• tm253966d1_8k.htm (8-K) — 28KB
• tm253966d1_ex99-1.htm (EX-99.1) — 13KB
• tm253966d1_ex99-1img001.jpg (GRAPHIC) — 3KB
• 0001104659-25-004967.txt ( ) — 222KB
• avbp-20250121.xsd (EX-101.SCH) — 3KB
• avbp-20250121_lab.xml (EX-101.LAB) — 33KB
• avbp-20250121_pre.xml (EX-101.PRE) — 22KB
• tm253966d1_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On January 21, 2025, ArriVent BioPharma, Inc. (the "Company") entered into an Exclusive License Agreement (the "Lepu Biopharma Agreement") with Lepu Biopharma Co., Ltd. ("Lepu Biopharma"), pursuant to which Lepu Biopharma granted the Company a right to develop and commercialize MRG007, an antibody drug conjugate for gastrointestinal cancers outside greater China, which is mainland China, Hong Kong, Macau and Taiwan ("Greater China"). Under the Lepu Biopharma Agreement, Lepu Biopharma granted to the Company: (i) an exclusive, royalty-bearing, sublicensable license under certain intellectual property owned or controlled by Lepu Biopharma, to develop, manufacture and commercialize any product containing MRG007 for all uses in all countries and territories other than Greater China (the "ArriVent Territory"); and (ii) a non-exclusive license under certain intellectual property controlled by Lepu Biopharma to develop, manufacture and commercialize any product containing MRG007 for use in oncology in the ArriVent Territory. Under the Lepu Biopharma Agreement, Lepu Biopharma is entitled to receive a one-time upfront payment and near-term milestone payments totaling $47.0 million in cash and is eligible to receive up to $1.16 billion in development, regulatory and sales milestones and tiered royalties in high single-digit to low-teen percentages on net sales in the ArriVent Territory. The Lepu Biopharma Agreement is subject to termination: (i) by either party, subject to specified cure periods, for the material breach by the other party or the bankruptcy or insolvency of the other party, (ii) by the Company for convenience, subject to a specified notice period, (iii) by Lepu Biopharma due to the Company's challenge of certain patents controlled by Lepu Biopharma, or (iv) by Lepu Biopharma due to the Company's failure to carry out certain diligence obligations. The foregoing summary of the Lepu Biopharma Agreement is

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 21, 2025, the Company issued a press release announcing the Lepu Biopharma Agreement. A copy of the press release is furnished as Exhibit 99.1 hereto. The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated January 21, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ARRIVENT BIOPHARMA, INC. By: /s/ Winston Kung Winston Kung Chief Financial Officer and Treasurer Date: January 21, 2025

View Full Filing

View this 8-K filing on SEC EDGAR